Business Context and Reporting Period
This Form 8-K filing by BIO-RAD LABORATORIES, INC. was submitted on April 2, 2019. The report discloses significant changes in executive leadership, specifically the appointment of a new Chief Financial Officer and the retirement of the incumbent.
Key Financial Metrics
The filing does not contain operational financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The financial information provided is limited to the compensation package for the newly appointed Executive Vice President and Chief Financial Officer, Ilan Daskal:
- Annual Base Salary: $500,000
- Target Cash Bonus: 65% of eligible earnings (pro-rated for 2019)
- Equity Grant: 3,500 restricted stock units and 3,500 non-qualified stock options (to be granted within 30 days of hire)
- Severance: One year of base salary if terminated without good cause, subject to a release of claims
Material Changes
The primary material change reported is the transition of the Chief Financial Officer role:
- Appointment: Ilan Daskal was appointed Executive Vice President and Chief Financial Officer, effective April 6, 2019.
- Retirement: Christine A. Tsingos retired as Executive Vice President and Chief Financial Officer effective April 5, 2019. She will remain employed until May 10, 2019, to assist with the transition.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, market outlook, or discussion of risks and contingencies. Management commentary is limited to the announcement of the leadership change and the background of the new appointee, who brings over 25 years of senior financial experience from companies including Lumileds, International Rectifier, and Cepheid.
Investor Verification Checklist
- Verify the effective dates of the CFO transition (April 5-6, 2019) and the interim support period ending May 10, 2019.
- Review the attached employment offer letter (Exhibit 10.1) for full details on equity vesting schedules and bonus eligibility.
- Confirm the absence of any undisclosed family relationships or material interests between Mr. Daskal and existing directors or officers.
- Note that this filing does not provide updated financial performance data; refer to the most recent 10-Q or 10-K for operational metrics.